PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting

LYT-100 demonstrated ~50% improvement versus pirfenidone in key adverse events at a comparable exposure level, which may lead to better patient compliance and improved treatment outcomes in...

Related Keywords

Hawaii ,United States ,Honolulu ,American ,Castro Pereira ,Los Angeles ,Julie Krop ,Toby Maher ,Twitter ,Puretech Health ,University Of Southern California ,Annals Of The American Thoracic Society ,Nasdaq ,Chief Medical Officer ,Interstitial Lung Disease ,Keck School ,Southern California ,Idiopathic Pulmonary Fibrosis ,Founded Entities ,Private Securities Litigation Reform Act ,Annual Report ,Idiopathic Pulmonary ,New England Journal ,Predicting Life Expectancy ,Managed Care ,Specialty Pharmacy ,Antifibrotic Medications Pirfenidone ,American Thoracic Society ,Markets ,